NCT00444561已完成2 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 184
- 试验地点
- 1
- 主要终点
- To evaluate various pharmacodynamic effects (including effects on body weight, food intake, and other parameters) of subcutaneously (SC) infused or injected pramlintide in obese subjects.
研究概览
简要总结
This exploratory study is designed to evaluate various pharmacodynamic effects of subcutaneously (SC) infused or injected pramlintide in obese, nondiabetic male and postmenopausal female (not on hormone replacement therapy) subjects. The study will also assess the safety and tolerability of pramlintide administered by SC infusion or injection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 25 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Is <6'3" (190.5 cm) tall and weighs <300 lb (~136.3 kg)
- •Is obese with a body mass index (BMI) >=30 kg/m^2 to <=45 kg/m^2 and with a history consistent with progressive weight gain and development of obesity not secondary to drastic or traumatic initiating events (e.g., excessive weight gain due to cessation of smoking)
- •Is a nonsmoker (never smoked or has not smoked for at least 2 years)
- •Does not have a clinical diagnosis of diabetes
- •Has not had a major change in daily physical activity within 2 months prior to study start (e.g., initiation of an exercise program)
- •Usually consumes three major meals (morning, midday, and evening) each day and rarely (less than once a week) wakes up to eat during the night
排除标准
- •Is currently enrolled in a weight loss program or plans to enroll in a weight loss or exercise program within the next 3 months
- •Is currently treated or expected to require or undergo treatment or has been treated within 2 months before screening with medications that are excluded:
- •Over the counter antiobesity agents including herbal supplements or prescription antiobesity agents approved for the long-term (including orlistat [Xenical] and sibutramine [Meridia]) and the short-term (including phentermine [Adipex-P, Celltech, Pro-Fast SA, Pro-Fast SR, Fastin, Oby trim, Zantryl, Teramine, Phentride, Phentercot, Obephen, Oby-cap], mazindol [Sanorex and Mazanor], methamphetamine [Desoxyn], diethylpropion [Tenuate and Tenuate Dospan], phendimetrazine [Bontril, Prelu-2, Melfiat 105, Unicelles, X-Trozine, Plegine, Adipost, Obezine, Phendiet-105, PT 105] and benzphetamine [Didrex]) treatment of obesity
- •Systemic steroids by oral, intravenous, or intramuscular route or potent topical steroids that are known to result in high systemic absorption
- •Alpha- or Beta-Blockers, centrally acting sympathicolytic or sympathicomimetic agents, reserpin, guanethidine, etc.
- •Psychotropic medications (e.g., tricyclic antidepressants, monoamine oxidase [MAO] inhibitors, selective serotonin reuptake inhibitors [SSRIs], neuroleptics, lithium, and benzodiazepines)
- •Hypnotic-sedative medications or medications that may affect sleeping behavior including medications containing caffeine
- •Drugs that directly affect gastrointestinal motility, including but not limited to: metoclopramide (Reglan®) and cisapride (Propulsid®); and macrolide antibiotics such as erythromycin and newer derivatives
- •Has received any investigational drug within 3 months before study start
- •Has participated previously in a study using pramlintide
研究组 & 干预措施
Pramlintide acetate (AC137)
Active Comparator
Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for SC administration. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43 mg/mL mannitol as an osmolality modifier and 2.25 mg/mL metacresol as a preservative. The concentration of pramlintide injection to be used in this study is 0.6 mg/mL.
干预措施: pramlintide acetate (Drug)
结局指标
主要结局
To evaluate various pharmacodynamic effects (including effects on body weight, food intake, and other parameters) of subcutaneously (SC) infused or injected pramlintide in obese subjects.
时间窗: 73 Days
次要结局
- To evaluate the safety and tolerability of SC infused or injected pramlintide in obese subjects.(73 Days)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's AtaxiaFriedreich AtaxiaNCT05579691Larimar Therapeutics, Inc.28
已完成
1 期
A Study of Injection HB0017 in Adult Healthy VolunteersHealthy SubjectsNCT04505033Huabo Biopharm Co., Ltd.40
已完成
1 期
Study of Evinacumab (REGN1500) in Caucasian and in Japanese Healthy VolunteersHealthy VolunteersNCT03146416Regeneron Pharmaceuticals96
进行中（未招募）
2 期
A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)Squamous Cell CarcinomaNCT06041802Merck Sharp & Dohme LLC19
已完成
3 期
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaHereditary Angioedema (HAE)NCT02584959Shire75